UB Paderborn / Katalog / Suche / in CDI

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

Journal of the American Society of Nephrology, 2004-08, Vol.15 (8), p.2208-2218

2004

Link zum Volltext

Verfügbarkeit prüfen

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

Kidney international, 2005-10, Vol.68 (4), p.1793-1800

2005

Link zum Volltext

Verfügbarkeit prüfen

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism

The journal of clinical endocrinology and metabolism, 2005-01, Vol.90 (1), p.135-141

2005

Link zum Volltext

Verfügbarkeit prüfen

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : A randomized, double-blind, multicenter study

Journal of the American Society of Nephrology, 2005-03, Vol.16 (3), p.800-807

2005

Link zum Volltext

Verfügbarkeit prüfen

Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis

JAMA : the journal of the American Medical Association, 2002-03, Vol.287 (12), p.1548

2002

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview

Clinical journal of the American Society of Nephrology, 2007-09, Vol.2 (5), p.898-905

2007

Link zum Volltext

Verfügbarkeit prüfen

Cinacalcet Hydrochloride Is an Effective Treatment for Secondary Hyperparathyroidism in Patients With CKD Not Receiving Dialysis

American journal of kidney diseases, 2005-07, Vol.46 (1), p.58-67

2005

Link zum Volltext

Verfügbarkeit prüfen

White blood cells as a novel mortality predictor in haemodialysis patients

Nephrology, dialysis, transplantation, 2003-06, Vol.18 (6), p.1167-1173

2003

Link zum Volltext

Verfügbarkeit prüfen

Predictors of proteinuria and renal failure among women with HIV infection

Kidney international, 2002-01, Vol.61 (1), p.195-202

2002

Link zum Volltext

Verfügbarkeit prüfen

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Diabetes care, 2013-12, Vol.36 (12), p.4022-4029

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2020-02, Vol.158 (3), p.550-561

2020

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients

American journal of kidney diseases, 2003-12, Vol.42 (6), p.1260-1269

2003

Link zum Volltext

Verfügbarkeit prüfen

Trends in anemia management among US hemodialysis patients

Journal of the American Society of Nephrology, 2002-05, Vol.13 (5), p.1288-1295

2002

Link zum Volltext

Verfügbarkeit prüfen

Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients

Nephrology, dialysis, transplantation, 2003-08, Vol.18 (8), p.1585-1591

2003

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

The European respiratory journal, 2019-10, Vol.54 (4), p.1901030

2019

Link zum Volltext

Verfügbarkeit prüfen

Slowing the progression of diabetic nephropathy and its cardiovascular consequences

The American heart journal, 2004-08, Vol.148 (2), p.243-251

2004

Link zum Volltext

Verfügbarkeit prüfen

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

Journal of Crohn's and colitis, 2021-06, Vol.15 (6), p.950-959

2021

Link zum Volltext

Verfügbarkeit prüfen

Systolic hypertension: An overview

The American heart journal, 2005-05, Vol.149 (5), p.769-775

2005

Link zum Volltext

Verfügbarkeit prüfen

764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S445-S446

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-665-S-665

2019

Link zum Volltext

Verfügbarkeit prüfen

Chronic kidney disease and cardiovascular risk: time to focus on therapy

Journal of the American Society of Nephrology, 2002-09, Vol.13 (9), p.2415-2416

2002

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member): 569

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S327-S328

2018

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

The American journal of gastroenterology, 2018-10, Vol.113, p.S327-S328

2018

Link zum Volltext

Verfügbarkeit prüfen

Regional variability in anaemia management and haemoglobin in the US

Nephrology, dialysis, transplantation, 2003-01, Vol.18 (1), p.147-152

2003

Link zum Volltext

Verfügbarkeit prüfen

FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Nephrology, dialysis, transplantation, 2018-05, Vol.33 (suppl_1), p.i9-i9

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis : A randomized, double-blind, multicenter study

Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview

Cinacalcet Hydrochloride Is an Effective Treatment for Secondary Hyperparathyroidism in Patients With CKD Not Receiving Dialysis

White blood cells as a novel mortality predictor in haemodialysis patients

Predictors of proteinuria and renal failure among women with HIV infection

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients

Trends in anemia management among US hemodialysis patients

Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

Slowing the progression of diabetic nephropathy and its cardiovascular consequences

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

Systolic hypertension: An overview

764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study

Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease

Chronic kidney disease and cardiovascular risk: time to focus on therapy

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member): 569

A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study

Regional variability in anaemia management and haemoglobin in the US

FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Suchergebnisse filtern